Urinary Aminopeptidase Activities as Early and Predictive Biomarkers of Renal Dysfunction in Cisplatin-Treated Rats by Quesada, Andrés et al.
Urinary Aminopeptidase Activities as Early and
Predictive Biomarkers of Renal Dysfunction in Cisplatin-
Treated Rats
Andrés Quesada1, Félix Vargas2, Sebastián Montoro-Molina1, Francisco O’Valle3, Marı́a
Dolores Rodrı́guez-Martı́nez3, Antonio Osuna4, Isabel Prieto1, Manuel Ramı́rez1,
Rosemary Wangensteen1*
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Abstract
This study analyzes the fluorimetric determination of alanyl- (Ala), glutamyl- (Glu), leucyl-cystinyl- (Cys) and aspartyl-
aminopeptidase (AspAp) urinary enzymatic activities as early and predictive biomarkers of renal dysfunction in cisplatin-
treated rats. Male Wistar rats (n = 8 each group) received a single subcutaneous injection of either saline or cisplatin 3.5 or
7 mg/kg, and urine samples were taken at 0, 1, 2, 3 and 14 days after treatment. In urine samples we determined Ala, Glu,
Cys and AspAp activities, proteinuria, N-acetyl-b-D-glucosaminidase (NAG), albumin, and neutrophil gelatinase-associated
lipocalin (NGAL). Plasma creatinine, creatinine clearance and renal morphological variables were measured at the end of the
experiment. CysAp, NAG and albumin were increased 48 hours after treatment in the cisplatin 3.5 mg/kg treated group. At
24 hours, all urinary aminopeptidase activities and albuminuria were significantly increased in the cisplatin 7 mg/kg treated
group. Aminopeptidase urinary activities correlated (p,0.011; r2.0.259) with plasma creatinine, creatinine clearance and/or
kidney weight/body weight ratio at the end of the experiment and they could be considered as predictive biomarkers of
renal injury severity. ROC-AUC analysis was made to study their sensitivity and specificity to distinguish between treated
and untreated rats at day 1. All aminopeptidase activities showed an AUC.0.633. We conclude that Ala, Cys, Glu and AspAp
enzymatic activities are early and predictive urinary biomarkers of the renal dysfunction induced by cisplatin. These
determinations can be very useful in the prognostic and diagnostic of renal dysfunction in preclinical research and clinical
practice.
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Introduction
Acute kidney injury (AKI) is a common clinical problem that is
defined by an abrupt increase in serum creatinine over 48 h
resulting from injury or insult that causes a functional or structural
change in the kidney. The main cause of AKI is the acute
apoptosis or necrosis of renal tubular cells, and the RIFLE (risk,
injury, failure, loss, and end-stage renal disease) classification
scheme is based in criteria of serum creatinine to classify renal
dysfunction in patients [1].
Nevertheless, traditionally used markers of AKI, such as blood
urea nitrogen (BUN) and creatinine are insensitive, nonspecific,
and do not adequately differentiate between the different stages of
AKI [2]. Serum creatinine accumulates over time, and changes in
creatinine concentrations become apparent only when the kidneys
have lost 50% of their functional capacity [3,4].
Early detection of AKI remains a challenge in both preclinical
research and clinical practice. There is an urgent need for better
biomarkers to permit more timely diagnosis of AKI, prediction of
injury severity, and safety assessment during drug development
[2].
Enzymes released from damaged tubular cells and excreted into
urine are the most promising biomarkers for an early detection of
AKI. They have an obvious diagnostic benefit because their
measurements may provide detailed information about the nature,
size and site of the damage to tubular cells and their possible
necrosis or dysfunction [5]. One of these enzymes, AlaAp (EC
3.4.11.2), is an enzyme of the brush border proposed in the early
seventies as a urinary marker of renal disease [6], and there is an
automatic photometric assay for its determination [7]. AlaAp,
together with GluAp (EC 3.4.11.7), CysAp (3.4.11.3) and AspAp
(EC 3.4.11.21) are present in the renal tubular cells [8–10] and
they have an aminopeptidasic function in angiotensin II metab-
olism, peptide that is increased in renal diseases. In our laboratory,
we have recently determined the activity of these four aminopep-
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tidases as an index of renal damage in salt-treated and
hyperthyroid rats [11].
In this work we investigated the reliability of the fluorimetric
determination of AlaAp, GluAp, CysAp and AspAp urinary
enzymatic activities as biomarkers of renal dysfunction induced by
cisplatin at two different doses (3.5 and 7 mg/kg) in rats. Cisplatin
is an antineoplastic drug known for its direct proximal tubular
nephrotoxicity in both humans and animals [12,13]. Rats treated
with one single dose of cisplatin at 7 mg/kg exhibit tubular
degeneration and necrosis [14] accompanied with a maximal
increase in the excretion of NAG [15], a renal tubular enzyme
[16], and glucosuria [15] at the third day of injection. At day 7,
plasma creatinine and BUN reach a maximum [15] and tubular
epithelial regeneration and dilatation are observed on day 8 after
treatment [14]. From day 14 to 56, development of tubulointer-
sticial fibrosis is observed in these rats with no differences in
urinary enzymes or glucose, but a significant increase in plasma
creatinine and BUN at day 56 [15].
We studied aminopeptidase activities as early biomarkers of
AKI and their ability to detect a slight renal damage evaluating
their increased urinary excretion at the first three days from
injection. We also analyzed their value as predictive biomarkers of
the severity of renal dysfunction by correlating the first day urinary
excretion level of the marker with two parameters of renal function
(plasma creatinine and creatinine clearance) and two parameters
of structural damage (renal hypertrophy and interstitial fibrosis).
We determined other parameters commonly used as urinary
biomarkers of renal damage (proteinuria, NAG, albumin, and
NGAL) and made combined ROC area under the curve (AUC)




All experimental procedures were performed according to the
European Union Guidelines to the Care and Use of Laboratory
Animals and approved by the Ethical Committee of the University
of Jaén with the approval ID R1/12/2010/66.
Animals and drugs
24 male Wistar rats weighing 227–279 g were purchased from
Harlan Laboratories (Barcelona, Spain). These rats were kept in a
room maintained at 2461uC and humidity of 55610%, with a 12-
Figure 1. Urinary aminopeptidase activities. AlaAp (A), GluAp (B), CysAp (C), and AspAp (D) urinary activities excreted per day and 100 g of rat
at 0, 1, 2 and 3 days of treatment in control, CisPt3.5 and CisPt7 groups. Data are means 6 SEM. a p,0.05, b p,0.01, c p,0.001 compared with
control group. d p,0.05, e p,0.01 compared with CisPt3.5 group.
doi:10.1371/journal.pone.0040402.g001
Urinary AP Activities in Cisplatin-Treated Rats
PLoS ONE | www.plosone.org 2 July 2012 | Volume 7 | Issue 7 | e40402
h light/dark cycle and had free access to rat chow and tap water.
Cisplatin (Sigma, Madrid, Spain) was dissolved in saline (1.5 and
3 mg/ml).
Experimental protocols
In order to examine the time course enzymatic activities, rats
were distributed in three groups: Control, CisPt3.5 and CisPt7,
(n = 8 each group), that received a subcutaneous injection of either
Figure 2. Proteinuria, albuminuria, NAG and NGAL excretion. Proteinuria (A), albuminuria (B), N-acetyl-b-D-glucosaminidase (C) and
neutrophil gelatinase-associated lipocalin (NGAL) excreted per day and 100 g of rat at 0, 1, 2 and 3 days of treatment in control, CisPt3.5 and CisPt7
groups. Data are means 6 SEM. a p,0.05, b p,0.01, c p,0.001 compared with control group. d p,0.05, e p,0.01 compared with CisPt3.5 group.
doi:10.1371/journal.pone.0040402.g002
Figure 3. Plasma creatinine, creatinine clearance and kidney weight/body weight ratio at the end of the experiment. Plasma
creatinine (A), creatinine clearance (B) and kidney weight/body weight ratio (C) at the end of the experiment in control, Cispt3.5 and CisPt7 groups.
*p,0.01, **p,0.001 compared with control group. + p,0.01, ++ p,0.001 compared with CisPt3.5 group.
doi:10.1371/journal.pone.0040402.g003
Urinary AP Activities in Cisplatin-Treated Rats
PLoS ONE | www.plosone.org 3 July 2012 | Volume 7 | Issue 7 | e40402
saline or cisplatin 3.5 mg/kg and 7 mg/kg, respectively. One day
before treatment and at 0, 1, 2 and 13 days after cisplatin or saline
administration, rats were housed in metabolic cages and 24-h
urine collection was made, obtaining urine samples at 0, 1, 2, 3
and 14 days. Urine samples were centrifuged 15 min at 1000 g,
aliquoted and frozen at 280uC until assay. At the end of the
experiment, blood samples were obtained from left ventricle under
anesthesia (pentobarbital, 50 mg/kg, i.p.), centrifuged 15 min at
1000 g, aliquoted and stored at 280uC. Kidneys were removed
and weighted. One kidney was fixed in 10% neutral-buffered
formalin solution during 24 h and subsequently placed in 70%
ethanol.
Analytical procedures
Ala, Glu, Cys and AspAp urinary activities were determined in
duplicate in a kinetic fluorimetric assay using alanyl-, glutamyl-,
cystinyl- and aspartyl-b-naphtylamide as substrates, respectively.
20 ml of urine were incubated during 30 min at 37uC with 90 ml of
their corresponding substrate solution (2.14 mg/dl alanyl-b-
naphtylamide, 10 mg/dl bovine serum albumin (BSA), 10 mg/dl
dithiotreitol (DTT) in pH 7.4 50 mM HCl-Tris; 2.72 mg/dl
glutamyl-b-naphtylamide, 10 mg/dl BSA, 10 mg/dl DTT and
555 mg/dl CaCl2 in pH 7.4 50 mM HCl-Tris; 5.63 mg/dl
cystinyl-b-naphtylamide, 10 mg/dl BSA, 10 mg/dl DTT in
pH 6 50 mM HCl-Tris; 2.58 mg/dl aspartyl-b-naphtylamide,
10 mg/dl BSA, 555 mg/dl CaCl2 in pH 7.4 50 mM HCl-Tris).
The substrates were previously dissolved in 1 ml of dimethyl
sulfoxide and stored at 220uC. The amount of b-naphtylamine
released as a result of the aminopeptidase activities was measured
fluorimetrically at an emission wavelength of 412 nm with an
excitation wavelength of 345 nm, and quantified using a standard
curve of b-naphtylamine (0–200 nmol/ml). Sample blanks were
made in duplicate using an incubation solution that did not
contain the substrate of the enzyme. Fluorimetric data from
samples, blanks and standard curve were taken each minute, and
fluorescence of sample blanks was subtracted from the fluores-
cence of the samples at each point. Specific aminopeptidase
activities were calculated from the slope of the linear portion of
Figure 4. Morphological changes and tubulointerstitial fibrosis in renal outer medulla induced by cisplatin. Left panel shows control
group without morphological lesion (A), CisPt3.5 (C) and CisPt7 (E) groups whit moderate nuclear dysplasia, incipient acute tubular necrosis, marked
tubular dilation and apoptotic cells in tubular lumen of proximal convoluted tubules in the corticomedullary junction (PAS original magnification
x200). Scale bar = 100 micrometers. Right panel shows representative photographs of Sirius red staining of kidneys from control (B), 3.5 (D) and
7 mg/kg cisplatin-treated rats (F) after 14 days (original magnification x200).
doi:10.1371/journal.pone.0040402.g004
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enzymatic assay obtaining nanomol of substrate hydrolyzed per ml
and minute. These values were normalized by diuresis and
expressed as absolute excretion per 100 g of rat and day.
Proteinuria was determined with the red pirogallol protein assay
(Spinreact, Barcelona, Spain). NAG was determined by a
colorimetric method purchased from Roche Diagnostics (Barce-
lona, Spain). Urinary albumin and NGAL were analyzed by
ELISA with kits purchased from Bethyl Laboratories (Montgom-
ery, TX, USA) and Bioporto Diagnostics (Gentofte, Denmark),
respectively. Plasma and urinary creatinine was measured by the
kinetic method of Jaffé, based on the reaction of creatinine with
sodium picrate.
These urinary parameters were measured at 0, 1, 2 and 3 days
from injection of cisplatin and expressed as absolute excretion per
100 g of rat and day. Plasma and urinary creatinine concentration
were measured at the end of the experiment.
Histopathological analysis
For conventional morphology, buffered 10% formaldehyde-
fixed, paraffin-embedded transversal kidney sections in horizontal
plane were stained with hematoxylin and eosin, Masson’s
trichrome and periodic acid-Schiff stain (PAS). The morphological
study was done in blinded fashion on 4-micrometer sections with
light microscopy, using the most appropriate stain for each lesion.
The severity of lesions was calculated semiquantitatively using a 0
to 3 scale (0, absence; 1, mild [,10% of juxtamedullary proximal
tubules, vessels or glomeruli involved]; 2, moderate [10 to 25%]; 3,
severe [.25%]).
Morphometrical analysis
Kidney samples fixed in buffered 10% formalin were embedded
in paraffin and serially sectioned at 5 mm thickness. Afterwards,
they were stained with 1% picro Sirius red F3BA (Gurr, BDH
Chemicals Ltd., Poole, United Kingdom) for image analysis
quantification. To improve staining, tissue sections were kept after
deparaffination for 3–5 days in 70% ethanol as mordent. Picro
Sirius red stains connective fibers deep red and cell nuclei and
cytoplasmatic structures light red/bright yellow [17].
To automatically quantify interstitial connective tissue and
glomerular morphometry on rats kidney histologic sections, we
developed several image processing algorithms that had been
brought together in one image analysis application, named
Fibrosis HRH [18]. We evaluated 20 images of corticomedullary
junction per kidney as previously described [18].
Statistical analyses
We used t test for the analysis of variables with normal
distribution. Mann-Whitney W (Wilcoxon) test was used to
analyze the differences in morphological variables between treated
and control rats. Differences were considered statistically signifi-
cant at P,0.05 level. Linear regression and analysis of variance
were made to establish the correlation of urinary biomarkers at the
first day with plasma creatinine, creatinine clearance, renal
hypertrophy and interstitial fibrosis at the end of the experiment.
P,0.05 and |r| .0.5 was considered as a strong correlation.
ROC-AUC analysis was made with JLABROC4 software [19].
We used the results obtained at 24 hours of treatment, and studied
the sensitivity and specificity of each marker to differentiate if a rat
had received cisplatin (either 3.5 or 7 mg/kg) or saline.
Table 1. Morphological and morphometrical variables
analyzed in kidney biopsies from Control, CisPt3.5 and CisPt7
rats at the end of the experiment.
Groups Control CisPt 3.5 CisPt 7
Displasia S3 segment 0.00 6 0.00 1.63 6 0.18** 2.75 6 0.16**,++
Acute tubular necrosis 0.00 6 0.00 1.13 6 0.23* 2.13 6 0.13**,+
Apoptosis 0.00 6 0.00 1.25 6 0.25* 2 6 0.27**
Tubular casts 0.00 6 0.0 0 0.13 6 0.13 1.38 6 0.26*,+
Tubular atrophy 0.00 6 0.00 0.00 6 0.00 0.13 6 0.13
Tubular dilation 0.00 6 0.00 1.00 6 0.19* 2.75 6 0.16**,++
Tubular vacuolization 0.00 6 0.00 0.00 6 0.00 0.00 6 0.00
Tubular mitosis 0.00 6 0.00 0.50 6 0.19 1.25 6 0.16**,+
Inflammatory infiltrate 0.00 6 0.00 0.20 6 0.20 0.50 6 0.33
Glomerular lesion 0.00 6 0.00 0.00 6 0.00 0.00 6 0.00
Vascular lesion 0.00 6 0.00 0.00 6 0.00 0.20 6 0.20
Fibrosis (%) 2.61 6 0.28 5.28 6 0.43** 5.36 6 0.50**
Fibrosis area (mm2) 3591 6 388 7194 6 548** 7361 6 660**
*p,0.01, **p,0.001 versus control group. +p,0.01, ++p,0.001 versus Cispt3.5
group. n = 8 each group.
doi:10.1371/journal.pone.0040402.t001
Figure 5. Linear regressions between urinary AlaAp activity at day 1 and plasma creatinine, creatinine clearance and kidney
weight/body weight at day 14. Linear regressions between AlaAp activity at day 1 and plasma creatinine (A), creatinine clearance (B) and kidney
weight/body weight (C) at the end of the experiment.
doi:10.1371/journal.pone.0040402.g005
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Results
Figure 1 shows the time course of aminopeptidase urinary
excretion in experimental groups. Ala, Glu, Cys and AspAp
activities were increased at day 1, 2 and 3 after treatment in
CisPt7 group. We also found a significantly increase of CysAp
activity at day 2 in CisPt3.5 group (Fig. 1C).
Albuminuria was increased at day 1, 2 and 3 in CisPt7 group,
while proteinuria, NAG and NGAL were increased at day 3
(Fig. 2). Albuminuria and NAG increased at day 2 and 3 in CisPt
3.5 group. Proteinuria and NGAL excretion were also significa-
tively augmented at day 3 in CisPt 3.5 group.
At the end of the experiment, CisPt7 group exhibited an
augmented plasma creatinine level, diminished creatinine clear-
ance and renal hypertrophy (Fig. 3), while CisPt3.5 group did not
show any statistically significative difference in these parameters
with respect to control group.
The renal lesions in Wistar control rats were absent. No
glomerular, tubulointerstitial or vascular lesions were present in
renal parenchyma. Histopathological examination of renal slices
from rats treated with 3.5 or 7 mg/kg of cisplatin showed different
alterations, including relevant nuclear dysplasia and incipient
acute tubular necrosis (Fig. 4). The sections of the kidney from
cisplatin-treated rats exhibited marked dilation of proximal
convoluted tubules in the corticomedullary junction with slogging
of almost entire epithelium due to desquamation of tubular
epithelium that induced a total absence of microvilli and loss of
brush border in CisPt7 group. Also, mild tubular atrophy and
apoptotic cells in tubular lumen were present in both cisplatin-
treated groups (Table 1). Statistical differences were found
between both cisplatin groups into morphological variables
analysis, indicating a dose-response relationship.
Cisplatin significantly enlarged the fibrosis area in the tubular
interstitium from CisPt3.5 and CisPt7 groups. The fibrosis area
was remarkably higher in the corticomedullary junction of the
kidney (Table 1, Fig. 4).
Significative correlations were found for Ala, Glu, Cys and
AspAp urinary activities at 24 hours of treatment with kidney
weight/body weight ratio at the end of the experiment. AlaAp and
CysAp activities correlated with creatinine clearance, and AlaAp
also correlated with plasma creatinine (Table 2, Fig. 5). We did not
found a correlation of any of biomarkers studied at this point with
renal fibrosis (Table 2).
AlaAp presented the largest ROC-AUC of all the markers
studied 24 hours after treatment (Fig. 6). Therefore, AlaAp
showed the maximum levels of specificity and sensitivity to detect
if an animal received cisplatin or saline and it was a perfect
discriminator between treated and untreated rats. GluAp, CysAp
and AspAp also had an AUC .0.5, as albuminuria and
proteinuria (Table 3), indicating that these enzymes could also
be considerated as biomarkers of renal dysfunction in this animal
model.
Discussion
The main finding of this article is that Ala, Glu, Cys, and AspAp
activities are early and predictive urinary biomarkers of the AKI
induced by cisplatin, and their determination could be very useful
in early detection and monitorization of renal damage.
Biochemical and histhopathological data obtained in our
experimental groups were in consonance with those obtained in
previous works by other authors [14,15] and confirmed the
effectiveness of cisplatin treatment producing renal injury, showing
similar increases in plasmatic creatinine, proteinuria and enzy-
muria at the same days of the study.
Ala, Glu and CysAp are highly organ-specific because they are
present in the brush border membrane of renal tubular cells [9]
and exhibit high molecular weights (.140 kDa) that make difficult
that their presence in urine could be due to alterations in
glomerular barrier. These enzymes participate in the intrarrenal
renin-angiotensin-aldosterone system (RAAS) [20]. It is known
that increased tubular absorption of filtered proteins induces
tubulointerstitial inflammation, ultimately resulting in tubular
Table 2. P-value and correlation coefficients (r and r2) of
linear regression between urinary biomarkers excreted at
day 1 versus kidney weight/body weight ratio, interstitial
fibrosis, plasma creatinine and creatinine clearance at day 14.
P value R R2
Kidney weight/body weight
AlaAp* 0.0002 0.690 0.477
CysAp* 0.0009 0.632 0.400
GluAp* 0.0040 0.565 0.319
AspAp* 0.0110 0.509 0.259
NGAL 0.2877 20.226 0.051
Proteinuria 0.4219 0.172 0.030
NAG 0.7564 0.067 0.447
Albumin 0.7056 0.081 0.007
Interstitial fibrosis
AlaAp 0.0621 0.386 0.149
Albumin 0.1473 0.305 0.093
CysAp 0.2410 0.249 0.062
AspAp 0.3673 0.193 0.037
GluAp 0.3843 0.186 0.035
NGAL 0.6847 20.087 0.008
Proteinuria 0.8324 0.046 0.002
NAG 0.9255 20.020 0.000
Plasma creatinine
AlaAp* 0.0053 0.550 0.303
CysAp 0.0561 0.395 0.156
Albumin 0.0607 0.388 0.151
AspAp 0.1650 0.293 0.086
GluAp 0.2437 0.247 0.061
NAG 0.2511 20.244 0.059
Proteinuria 0.8290 20.047 0.217
NGAL 0.8905 20.030 0.088
Creatinine clearance
AlaAp* 0.0001 20.712 0.507
CysAp* 0.0015 20.611 0.374
GluAp 0.0142 20.494 0.244
AspAp 0.0158 20.487 0.237
Albumin 0.1036 20.340 0.116
Proteinuria 0.4234 20.174 0.029
NGAL 0.7485 0.069 0.005
NAG 0.9409 0.016 0.000
*p,0.05 and |r| .0.5.
Biomarkers are rank ordered for p-value from top to bottom.
doi:10.1371/journal.pone.0040402.t002
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atrophy, interstitial fibrosis, and loss of renal function [21]. In the
proximal tubule, albumin and other ultrafiltered proteins are
reabsorbed by endocytosis involving megalin and cubulin [22].
AngII stimulates albumin endocytosis in proximal tubule cells via
AT2 receptor–mediated protein kinase B activation. However, an
increase in tubular albumin reabsorption activates the tubular
RAAS, leading to a vicious circle [23] that could explain the
elevated urinary activities of these enzymes when they are released
from the brush border to the ultrafiltrate after cisplatin injection.
In consequence, AlaAp activity has been widely used as a
marker of renal dysfunction in animal models of nephrotoxicity
induced with vancomicine [24] or amphotericin B [25], or in
human diseases like glomerulopathies [26], IgA nephropathy [27],
rheumatoid arthritis [28] or diabetes [29], and there are
contradictory results about its utility as a marker in kidney
transplanted patients [30,31].
The high correlation of urinary activities of Glu, Ala, Cys and
AspAp at day 1 with kidney weight/body weight ratio, and of Ala
and CysAp with creatinine clearance at day 14 shows their
predictive value over renal dysfunction and structural damage.
AlaAp also correlates with plasma creatinine at day 14. Never-
theless, there is no correlation in any of the biomarkers studied
with renal fibrosis. Kawai et al [15] concluded that fibrosis is a
process of resolution from acute tubular injury induced by cisplatin
and, in our study, we also have found an increase in the area of
interstitial fibrosis at day 14 in the two groups of animals treated
Figure 6. ROC curves for urinary aminopeptidase activities at day 1. ROC curves showing specificity and sensitivity for AlaAp (A), GluAp (B),
CysAp (C) and AspAp (D) urinary activities at the first day of treatment.
doi:10.1371/journal.pone.0040402.g006
Table 3. ROC-Area under the curve (AUC), sensitivity at 95%
specificity (Sens 95%) and fold-cutoff relative to controls to
achieve 95% specificity (threshold) of urinary biomarkers
excreted at day 1 in control (true negative) and cisplatin 3.5 or
7 mg/kg (true positive) treated rats.
AUC Sens 95% Threshold
AlaAp 0.89460.067 0.6090 1.7394
CysAp 0.86060.079 0.4757 1.6209
Albumin 0.80660.087 0.5321 1.7196
GluAp 0.71460.119 0.0895 1.7079
Proteinuria 0.70960.114 0.1354 1.6543
AspAp 0.63360.125 0.0683 1.6299
NAG 0.45360.114 0.1492 1.5392
NGAL 0.37760.124 0.0129 1.7247
Biomarkers are rank ordered for AUC from top to bottom.
doi:10.1371/journal.pone.0040402.t003
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with cisplatin. The lack of correlation of all urinary biomarkers
with renal fibrosis may indicate that the extent of fibrotic lesions is
not directly related with the tubular injury evoked by cisplatin at
24 hours. In fact, the group treated with the submaximal dose of
cisplatin showed a fibrosis area similar to the group treated with
7 mg/kg. Nevertheless, the CisPt3.5 group had unaltered kidney
weight/body weight, plasma creatinine or creatinine clearance.
This would indicate that the alterations in renal function observed
in CisPt7 group are more dependent of other factors like tubular
dilation or dysplasia rather than of the fibrotic process.
Interestingly, the rest of the markers studied did not correlate
with any parameter of renal dysfunction or structural damage, and
albuminuria was the only marker that was slightly increased at
24 hours in CisPt7 group. Low-molecular weight proteins like
albumin can pass through glomerular barrier and, therefore,
urinary proteins and albumin may have an extrarrenal origin in
other patologies. In a previous study, albuminuria has been related
with cardiovascular events like endothelial injury that presents
collateral kidney damage [32]. Therefore, the urinary levels of
albumin or total proteins may be influenced by their plasmatic
concentration, making difficult to elucidate in some cases if their
presence in urine is exclusively due to the renal alterations. In our
experiment, the slight elevation of albuminuria at 24 hours in
CisPt7 group may be probably related with the reduction in the
tubular reabsorption of this protein due to the release of
aminopeptidases from microvilli, because these enzymes were
the only markers that were increased at this point.
24 hours after treatment there were no differences in the
excretion of NAG and NGAL in the animals treated with the
submaximal or the maximal dose of cisplatin versus control group.
Therefore, in this model, NAG and NGAL could not detect the
renal damage evoked with cisplatin as early as aminopeptidase
activities or albuminuria and they do not predict renal alterations
24 hours after treatment as Ala, Glu, Cys or AspAp activities do.
NAG and NGAL are implicated in several tubular functions that
include transport of proteins [16] and hydrophobic molecules [33]
through membranes, respectively. Our findings suggest that the
release of aminopeptidases from brush border precedes in time to
the alterations in these renal tubular functions in this model. NAG
and albuminuria started to increase at day 2 in CisPt3.5 group,
and NGAL and proteinuria at day 3, while aminopeptidase
activities were not significatively increased, except a slight increase
in CysAp activity at day 2. This would indicate that the
submaximal dose of cisplatin evokes alterations in renal tubular
transport functions that are similar to the alterations observed with
the maximal dose of cisplatin. In fact, there were no differences in
the excretion of protein, albumin, NAG and NGAL between
CisPt3.5 and CisPt7 group. Nevertheless, this tubular dysfunction
is not accompanied with a significative loss of brush border
enzymes or, at least, it is not sufficiently remarkable with this
submaximal dose.
In conclusion, Ala, Glu, Cys and AspAp enzymatic activities are
early and predictive biomarkers of the AKI induced by cisplatin.
The four markers show high sensitivity and specificity to
distinguish nephrotoxicant-treated from control rats. These
determinations could be very useful in the prognostic and
diagnostic of renal dysfunction in preclinical research and clinical
practice, because the urine sample does not need any special
treatment and the laboratory test is simple, quick and inexpensive
in comparison with other techniques that require expensive
antibodies and large periods of incubation, like ELISA or Western
blot, that sometimes make difficult their serial determination.
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